ITMI991582A1 - Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala - Google Patents
Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala Download PDFInfo
- Publication number
- ITMI991582A1 ITMI991582A1 IT1999MI001582A ITMI991582A ITMI991582A1 IT MI991582 A1 ITMI991582 A1 IT MI991582A1 IT 1999MI001582 A IT1999MI001582 A IT 1999MI001582A IT MI991582 A ITMI991582 A IT MI991582A IT MI991582 A1 ITMI991582 A1 IT MI991582A1
- Authority
- IT
- Italy
- Prior art keywords
- particles
- process according
- powder
- vehicle
- preparation
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims description 125
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title description 23
- 239000000428 dust Substances 0.000 title description 5
- 239000000843 powder Substances 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 54
- 230000008569 process Effects 0.000 claims description 37
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 32
- 229940079593 drug Drugs 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 32
- 239000008101 lactose Substances 0.000 claims description 31
- 229960001375 lactose Drugs 0.000 claims description 31
- 238000002156 mixing Methods 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000654 additive Substances 0.000 claims description 15
- 238000009499 grossing Methods 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 12
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 230000003746 surface roughness Effects 0.000 claims description 9
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 5
- 238000005498 polishing Methods 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 229940097362 cyclodextrins Drugs 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- 238000009736 wetting Methods 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 229960002848 formoterol Drugs 0.000 claims description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229960001361 ipratropium bromide Drugs 0.000 claims description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical group O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 229960002052 salbutamol Drugs 0.000 claims description 2
- 229960004017 salmeterol Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229960001609 oxitropium bromide Drugs 0.000 claims 1
- LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 claims 1
- 239000003981 vehicle Substances 0.000 description 54
- 239000010419 fine particle Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 8
- 238000012387 aerosolization Methods 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000008021 deposition Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000007517 polishing process Methods 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 101150034459 Parpbp gene Proteins 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 aliphatic alcohols Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
- Y10T428/2998—Coated including synthetic resin or polymer
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI001582A ITMI991582A1 (it) | 1999-07-16 | 1999-07-16 | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| BR0012351-0A BR0012351A (pt) | 1999-07-16 | 2000-07-13 | Pós consistindo de partìculas com uma superfìcie perfeitamente macia, para uso como veìculos para a preparação de misturas de inalação com medicamentos micronizados e o método para sua preparação |
| DK00956180T DK1196146T3 (da) | 1999-07-16 | 2000-07-13 | Pulverpartikler med glat overflade til anvendelse i inhalationsterapi |
| EP00956180A EP1196146B1 (fr) | 1999-07-16 | 2000-07-13 | Poudres composees de particules ayant une surface lisse pour une utilisation en therapie inhalative |
| PT00956180T PT1196146E (pt) | 1999-07-16 | 2000-07-13 | Partículas de pó com superfície lisa para utilização em terapêutica de inalação |
| DE60030721T DE60030721T2 (de) | 1999-07-16 | 2000-07-13 | Pulverpartikel mit glatter oberfläche zur verwendung in der inhalationstherapie |
| ES00956180T ES2272313T3 (es) | 1999-07-16 | 2000-07-13 | Particulas en polvo con superficie lisa para usar en terapia de inhalacion. |
| PCT/EP2000/006690 WO2001005429A2 (fr) | 1999-07-16 | 2000-07-13 | Poudres composees de particules ayant une surface parfaitement lisse, utilisees comme excipients dans la preparation de melanges d'inhalation avec des medicaments micronises et methode de preparation |
| US10/030,686 US6780508B1 (en) | 1999-07-16 | 2000-07-13 | Powder particles with smooth surface for use in inhalation therapy |
| AU68232/00A AU6823200A (en) | 1999-07-16 | 2000-07-13 | Powders consisting of particles with a perfectly smooth surface, for use as carriers for the preparation of inhalation mixtures with micronized drugs and methodfor their preparation |
| AT00956180T ATE339191T1 (de) | 1999-07-16 | 2000-07-13 | Pulverpartikel mit glatter oberfläche zur verwendung in der inhalationstherapie |
| SI200030911T SI1196146T1 (sl) | 1999-07-16 | 2000-07-13 | Praĺ kasti delci z gladko povrĺ ino za uporabo pri inhalacijski terapiji |
| US10/806,240 US7399528B2 (en) | 1999-07-16 | 2004-03-23 | Powder particles with smooth surface for use in inhalation therapy |
| CY20061101710T CY1106269T1 (el) | 1999-07-16 | 2006-11-28 | Σωματιδια σκονης με λεια επιφανεια για χρηση σε θepαπεια με εισπνοη |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999MI001582A ITMI991582A1 (it) | 1999-07-16 | 1999-07-16 | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITMI991582A0 ITMI991582A0 (it) | 1999-07-16 |
| ITMI991582A1 true ITMI991582A1 (it) | 2001-01-16 |
Family
ID=11383357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT1999MI001582A ITMI991582A1 (it) | 1999-07-16 | 1999-07-16 | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6780508B1 (fr) |
| EP (1) | EP1196146B1 (fr) |
| AT (1) | ATE339191T1 (fr) |
| AU (1) | AU6823200A (fr) |
| BR (1) | BR0012351A (fr) |
| CY (1) | CY1106269T1 (fr) |
| DE (1) | DE60030721T2 (fr) |
| DK (1) | DK1196146T3 (fr) |
| ES (1) | ES2272313T3 (fr) |
| IT (1) | ITMI991582A1 (fr) |
| PT (1) | PT1196146E (fr) |
| SI (1) | SI1196146T1 (fr) |
| WO (1) | WO2001005429A2 (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| PT1920763E (pt) | 2000-11-30 | 2014-06-25 | Vectura Ltd | Composições farmacêuticas para inalação |
| EP1337239B2 (fr) | 2000-11-30 | 2015-11-25 | Vectura Limited | Particules servant dans une composition pharmaceutique |
| WO2003024396A2 (fr) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Formulations de medicament en poudre seche |
| DE60318938T2 (de) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | Inhalationsgerät |
| GB0210527D0 (en) * | 2002-05-08 | 2002-06-19 | Univ Bath | Process for the treatment of particles for use in pharmaceutical formulations |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| ITMI20040795A1 (it) * | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
| WO2005104712A2 (fr) | 2004-04-23 | 2005-11-10 | Cydex, Inc. | Formulation pour inhalateurs a poudre seche contenant de la cyclodextrine d'ether de sulfoalkyle |
| GB0409197D0 (en) | 2004-04-24 | 2004-05-26 | Innovata Biomed Ltd | Device |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| JP4990142B2 (ja) | 2004-08-23 | 2012-08-01 | マンカインド コーポレイション | 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩 |
| KR20070119631A (ko) | 2005-02-10 | 2007-12-20 | 글락소 그룹 리미티드 | 사전-분류 기술을 이용한 락토오스 제조 공정 및 이로부터제조된 약제 제형 |
| AU2006228536A1 (en) * | 2005-03-31 | 2006-10-05 | Rafael Armament Development Authority Ltd. | Spherically shaped substances |
| HUE028691T2 (en) | 2005-09-14 | 2016-12-28 | Mannkind Corp | A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| WO2007127163A2 (fr) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Méthode et composition pour le traitement d'une tumeur du snc |
| EP1944018A1 (fr) | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation |
| DE102008014237A1 (de) * | 2008-03-14 | 2009-09-17 | J. Rettenmaier & Söhne Gmbh + Co. Kg | Direktverpressbares Tablettierhilfsmittel |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2655921T3 (es) | 2008-06-13 | 2018-02-22 | Mannkind Corporation | Un inhalador de polvo seco y sistema para administración de fármacos |
| ES2904623T3 (es) | 2008-06-20 | 2022-04-05 | Mannkind Corp | Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| EP2191821A1 (fr) | 2008-11-26 | 2010-06-02 | CHIESI FARMACEUTICI S.p.A. | Microparticles contenant une sel de 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone avec adhesion ameliorée pour l'inhalation de poudre sèche |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP2221048A1 (fr) * | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Compositions pharmaceutiques pour l'inhalation |
| WO2010097188A1 (fr) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde |
| RU2487731C2 (ru) | 2009-03-04 | 2013-07-20 | Маннкайнд Корпорейшн | Усовершенствованная система доставки сухого порошкообразного лекарственного средства |
| EP2405963B1 (fr) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Appareil, système et procédé de mesure de résistance d'un inhalateur |
| WO2010144789A2 (fr) | 2009-06-12 | 2010-12-16 | Mannkind Corporation | Microparticules de dicétopipérazine avec des surfaces spécifiques définies |
| US8962063B2 (en) * | 2009-08-27 | 2015-02-24 | St.Unm | Methods and systems for dosing and coating inhalation powders onto carrier particles |
| WO2011056889A1 (fr) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | Appareil et méthode de simulation d'efforts d'inhalation |
| AU2010319328A1 (en) | 2009-11-12 | 2012-05-31 | Stc.Unm | Dry powder inhaler with flutter dispersion member |
| EP2360147A1 (fr) | 2010-02-22 | 2011-08-24 | CHIESI FARMACEUTICI S.p.A. | Procédé de préparation de particules crystallines d'un sel de 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol) |
| TR201811349T4 (tr) | 2010-04-01 | 2018-09-21 | Chiesi Farm Spa | İnhalasyon i̇çi̇n kuru toz taşiyici parti̇külleri̇n hazirlanmasi i̇çi̇n proses. |
| KR20130117755A (ko) | 2010-06-21 | 2013-10-28 | 맨카인드 코포레이션 | 건조 분말 약물 운반 시스템 및 방법 |
| US8561609B2 (en) | 2010-12-07 | 2013-10-22 | Respira Therapeutics, Inc. | Dry powder inhaler |
| CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
| WO2012174472A1 (fr) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | Microparticules de dicétopipérazine de capacité élevée |
| WO2013063160A1 (fr) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Procédés et compositions pour traiter la douleur |
| US9603906B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Inhalable liquid formulations of DNase I |
| US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
| CN108057154B (zh) | 2012-07-12 | 2021-04-16 | 曼金德公司 | 干粉药物输送系统和方法 |
| US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
| JP6523247B2 (ja) | 2013-03-15 | 2019-05-29 | マンカインド コーポレイション | 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法 |
| EP3021834A1 (fr) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Compositions pharmaceutiques en poudre sèche stables à la chaleur et procédés |
| EP3030294B1 (fr) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Appareil d'insufflation |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US20170304459A1 (en) | 2014-10-10 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
| MX2017009112A (es) | 2015-01-14 | 2018-06-15 | Respira Therapeutics Inc | Metodos y dispositivos de dispersion de polvo. |
| JP7455144B2 (ja) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法 |
| WO2023150747A1 (fr) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Compositions de poudre sèche de bédaquiline et de sels et leurs méthodes d'utilisation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1242211A (en) | 1967-08-08 | 1971-08-11 | Fisons Pharmaceuticals Ltd | Pharmaceutical composition |
| GB1381872A (en) | 1971-06-22 | 1975-01-29 | Fisons Ltd | Pharmaceutical compositions for inhalation |
| GB1520247A (en) | 1974-08-10 | 1978-08-02 | Fisons Ltd | Pelletised medicament formulations |
| GB1571629A (en) | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
| US4349542A (en) * | 1979-06-08 | 1982-09-14 | National Research Development Corporation | Mixture containing active ingredient and dendritic crystalline sugar for tableting |
| IT1204826B (it) | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche per inalazione |
| US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
| GB9001635D0 (en) * | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
| IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
| DE4140689B4 (de) | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| AU660824B2 (en) | 1992-06-12 | 1995-07-06 | Teijin Limited | Pharmaceutical preparation for intra-airway administration |
| US5603960A (en) * | 1993-05-25 | 1997-02-18 | O'hagan; Derek T. | Preparation of microparticles and method of immunization |
| GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
| DE4425255A1 (de) * | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| SE9700136D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| SE9700134D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| JP4090529B2 (ja) | 1996-01-24 | 2008-05-28 | フロイント産業株式会社 | 乳糖の球形粒及びその製造方法 |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP0903823B1 (fr) * | 1997-09-22 | 2002-12-11 | Osram Opto Semiconductors GmbH & Co. OHG | Elément laser comprenant un réseau de lasers et méthode de fabrication |
| PT1283036E (pt) | 1998-11-13 | 2008-03-06 | Jagotec Ag | Inalador de pó seco de dose múltipla com um reservatório de pó |
| GB9826783D0 (en) | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
| TR200102567T2 (tr) | 1999-03-05 | 2002-01-21 | Chiesi Farmaceutici S.P.A. | İnhalasyon için geliştirilmiş toz halindeki farmasötik bileşimler |
| IT1309592B1 (it) * | 1999-03-05 | 2002-01-24 | Chiesi Farma Spa | Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e |
-
1999
- 1999-07-16 IT IT1999MI001582A patent/ITMI991582A1/it unknown
-
2000
- 2000-07-13 DK DK00956180T patent/DK1196146T3/da active
- 2000-07-13 EP EP00956180A patent/EP1196146B1/fr not_active Revoked
- 2000-07-13 WO PCT/EP2000/006690 patent/WO2001005429A2/fr active IP Right Grant
- 2000-07-13 ES ES00956180T patent/ES2272313T3/es not_active Expired - Lifetime
- 2000-07-13 PT PT00956180T patent/PT1196146E/pt unknown
- 2000-07-13 US US10/030,686 patent/US6780508B1/en not_active Expired - Lifetime
- 2000-07-13 AU AU68232/00A patent/AU6823200A/en not_active Abandoned
- 2000-07-13 BR BR0012351-0A patent/BR0012351A/pt not_active Application Discontinuation
- 2000-07-13 AT AT00956180T patent/ATE339191T1/de active
- 2000-07-13 DE DE60030721T patent/DE60030721T2/de not_active Expired - Lifetime
- 2000-07-13 SI SI200030911T patent/SI1196146T1/sl unknown
-
2004
- 2004-03-23 US US10/806,240 patent/US7399528B2/en not_active Expired - Lifetime
-
2006
- 2006-11-28 CY CY20061101710T patent/CY1106269T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7399528B2 (en) | 2008-07-15 |
| SI1196146T1 (sl) | 2007-06-30 |
| DE60030721D1 (de) | 2006-10-26 |
| EP1196146A2 (fr) | 2002-04-17 |
| US6780508B1 (en) | 2004-08-24 |
| BR0012351A (pt) | 2002-06-11 |
| DK1196146T3 (da) | 2007-01-29 |
| PT1196146E (pt) | 2007-01-31 |
| ATE339191T1 (de) | 2006-10-15 |
| AU6823200A (en) | 2001-02-05 |
| WO2001005429A3 (fr) | 2001-10-04 |
| ES2272313T3 (es) | 2007-05-01 |
| US20050118113A1 (en) | 2005-06-02 |
| ITMI991582A0 (it) | 1999-07-16 |
| DE60030721T2 (de) | 2007-09-13 |
| WO2001005429A2 (fr) | 2001-01-25 |
| CY1106269T1 (el) | 2011-10-12 |
| EP1196146B1 (fr) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ITMI991582A1 (it) | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala | |
| ITMI990455A1 (it) | Particelle veicolo modificate da utilizzarsi nella preparazione di formulazioni farmaceutiche sotto forma di polimeri per inalazione e loro | |
| AU784719B2 (en) | Improvements in or relating to formulations for use in inhaler devices | |
| US7541022B2 (en) | Pharmaceutical formulations for dry powder inhalers | |
| JP2020518620A (ja) | 肺、鼻、舌下および／または咽頭への送達に適した、少なくとも１つの生物活性化合物をロードした多孔質シリカ粒子の製造方法 | |
| US10709666B2 (en) | Carrier particles for dry powder formulations for inhalation | |
| JP5698423B2 (ja) | 医薬組成物で使用するための粒子の製造法 | |
| JP2012524817A (ja) | 標的粒子サイズを有する、活性医薬を含む凝集体配合物 |